Bristol Myers Squibb (BMY) director reports new deferred share units
Rhea-AI Filing Summary
Bristol Myers Squibb director Michael R. McMullen reported an equity-based compensation change involving derivative securities. On 12/31/2025, he acquired 648.869 Deferred Share Units at a price of $0, which are linked to Bristol Myers Squibb common stock with a par value of $0.10 per share.
After this transaction, McMullen beneficially owns 10,860.897 Deferred Share Units in direct form. Each Deferred Share Unit converts into one share of common stock upon settlement, which occurs when he ceases to be a director or at a future date he previously specified. These units also reflect deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 648.869 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
FAQ
What insider transaction did Bristol Myers Squibb (BMY) report for Michael R. McMullen?
Michael R. McMullen, a director of Bristol Myers Squibb, reported acquiring 648.869 Deferred Share Units on 12/31/2025 at a price of $0 per unit.
Is this Bristol Myers Squibb (BMY) Form 4 transaction a direct or indirect holding?
The 10,860.897 Deferred Share Units reported by Michael R. McMullen are held in direct form.
AI-generated analysis. How Rhea-AI works. Not financial advice.